Supernus Pharmaceuticals, Inc. (SUPN) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Vericel Corp.

Harmony Biosciences Holdings, Inc.

Crinetics Pharmaceuticals, Inc.

IDEAYA Biosciences, Inc.

Supernus Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc.

Ultragenyx Pharmaceutical, Inc.

PTC Therapeutics, Inc.

Xenon Pharmaceuticals, Inc.

Biohaven Ltd.

Neumora Therapeutics, Inc.

Why is Supernus Pharmaceuticals, Inc. ?

Negative results in Jun 26

NET PROFIT(Q) At USD -5.85 MM has Fallen at -43.91%
OPERATING CASH FLOW(Y) Lowest at USD 19.91 MM
ROCE(HY) Lowest at -10.49%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 10.18%, its profits have fallen by -128%

Underperformed the market in the last 1 year

The stock has generated a return of 10.18% in the last 1 year, much lower than market (S&P 500) returns of 21.51%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Supernus Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Supernus Pharmaceuticals, Inc.

10.18%

2.20

35.73%

S&P 500

21.51%

1.63

13.19%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.68%

EBIT Growth (5y)

-174.78%

EBIT to Interest (avg)

19.82

Debt to EBITDA (avg)

0.16

Net Debt to Equity (avg)

-0.44

Sales to Capital Employed (avg)

0.65

Tax Ratio

32.55%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

10.50%

ROE (avg)

7.61%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.69

EV to EBIT

-59.71

EV to EBITDA

52.35

EV to Capital Employed

3.34

EV to Sales

3.55

PEG Ratio

Dividend Yield

ROCE (Latest)

-5.60%

ROE (Latest)

-1.79%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

NET PROFIT(HY)

Higher at USD -7.25 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.14 times

DEBTORS TURNOVER RATIO(HY)

Highest at 4.71 times

NET SALES(Q)

Highest at USD 219.06 MM

PRE-TAX PROFIT(Q)

At USD -5.13 MM has Grown at 43.64%

-25What is not working for the Company

NET PROFIT(Q)

At USD -5.85 MM has Fallen at -43.91%

OPERATING CASH FLOW(Y)

Lowest at USD 19.91 MM

ROCE(HY)

Lowest at -10.49%

RAW MATERIAL COST(Y)

Grown by 5.35% (YoY

INTEREST(Q)

Highest at USD 2.31 MM

EPS(Q)

Lowest at USD -1.01

Here's what is working for Supernus Pharmaceuticals, Inc.

Net Sales

Highest at USD 219.06 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Pre-Tax Profit

At USD -5.13 MM has Grown at 43.64%

over average net sales of the previous four periods of USD -9.1 MM

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Inventory Turnover Ratio

Highest at 3.14 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 4.71 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Supernus Pharmaceuticals, Inc.

Net Profit

At USD -5.85 MM has Fallen at -43.91%

over average net sales of the previous four periods of USD -4.07 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest

At USD 2.31 MM has Grown at inf%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Operating Cash Flow

Lowest at USD 19.91 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Interest

Highest at USD 2.31 MM

in the last five periods and Increased by inf% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

EPS

Lowest at USD -1.01

in the last five periods

MOJO Watch

Declining profitability; company has created lower earnings for shareholders

EPS (USD)

Raw Material Cost

Grown by 5.35% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales